Happy New Year – 2016

It’s been an interesting year. When I started this site I really didn’t know what was going to happen… in most respects, it has exceeded my expectations. A Few Opening Remarks On a positive note, I genuinely felt support for the mission of trying to create a fresh dialogue around the quality and transparency of ASX-listed companies operating in this…

Regeneus’ Mushroom Shareholders

One of the things I really dislike about the dynamic of the ASX is the false attribution of “quality” to the existence of any kind of analyst coverage. At least when one of the usual personalities like Smith, Sinatra, Stanton or Storey (I fondly think of them as the “S”-men) posts coverage you know, transparently, they…

Clinical Trial Communication Matters

Over the past few months I have poked several companies in the eye for the appalling quality of their clinical communication. I have specifically paid attention to Novogen (ASX : NRT), Benitec (ASX : BLT), Regeneus (ASX : RGS) and a few others. It is my position is that there is a consistently low quality and sensationalist ethos…

The Shock Jock : Market Roundup

You give me a royal pain in the ass, if you want to know the truth. – Holden (J.D. Salinger) When I announced earlier in the week that I would no longer be commenting on HotCopper, I thought that would be the end of the annoying, low-intelligence comments mostly aimed at some degree of personal…

Regeneus : Truly one of a kind…

That’s right, folks. Regeneus has a product development strategy that is unlike any other company in the entire world of biotechnology. It has decided to develop its products from “Man to Mouse”. You read correctly… While most of the rest of the biotechnology industry at least attempts to take a slightly cautious approach toward developing and…